Effect of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate on experimental herpes simplex keratitis.
Treatment of established experimental keratitis caused by herpes simplex virus with 9-beta-d-arabinofuranosyladenine 5'-monophosphate (Ara-AMP) or 9-beta-d-arabinofuranosylhypoxanthine 5'-monophosphate (Ara-HxMP) showed that the Ara-AMP, in a concentration of 2 or 20%, had a significant effect on the keratitis but that 0.4% Ara-HxMP showed only minimal activity. Ara-AMP was also effective in the treatment of idoxuridine-resistant keratitis. No local toxicity with a high concentration (20%) of Ara-AMP was seen, but the duration of therapy was brief.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001089:Arabinose / Q000031:analogs & derivatives / Q000627:therapeutic use; D007291:Inosine Monophosphate / Q000627:therapeutic use*; D007292:Inosine Nucleotides / Q000627:therapeutic use*; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D011817:Rabbits; D014740:Vidarabine / Q000627:therapeutic use*
D000998:Antiviral Agents; D007292:Inosine Nucleotides; D007291:Inosine Monophosphate; D001089:Arabinose; D014740:Vidarabine